Here Are the Facts You Need to Understand BBIO

By Chris Stiles • Monday, May 11 10:53 • Permanent Link

BridgeBio Pharma sank -2.3% today, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

BridgeBio Pharma has moved 88.9% over the last year, and the S&P 500 logged a change of 26.6%
BBIO has an average analyst rating of buy and is -35.36% away from its mean target price of $101.87 per share
Its trailing earnings per share (EPS) is $-3.74
BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -17.6 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.05 and its forward P/E ratio is 62.7
BridgeBio Pharma is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $-325290624, which refers to the total sum of all its inflows and outflows of cash over the last quarter
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.